A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa; Epoetin alfa; Epoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms Pyrenees
- Sponsors Astellas Pharma BV
- 11 Oct 2019 According to a FibroGen media release, data will be presented at the American Society of Nephrology Kidney Week 2019.
- 26 May 2019 Trial has been completed in Croatia.
- 10 May 2019 Data from pooled analysis of phase 3 trials (OLYMPUS, ALPS, ANDES, HIMALAYAS,ROCKIES, SIERRAS and PYRENEES ) presented in an AstraZeneca Media Release.